Get the Stockscreener App
0.7921
2.81%
0.0216
Immuron Limited Adr stock is traded at $0.7921, with a volume of 1,401.
It is up +2.81% in the last 24 hours and down -5.67% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$0.7705
Open:
$0.824
24h Volume:
1,401
Relative Volume:
0.03
Market Cap:
$6.61M
Revenue:
$4.83M
Net Income/Loss:
$-2.99M
P/E Ratio:
-1.6488
EPS:
-0.4804
Net Cash Flow:
$-2.83M
1W Performance:
+11.72%
1M Performance:
-5.67%
6M Performance:
-59.06%
1Y Performance:
-55.99%
1-Day Range:
$0.8089
$0.824
1-Week Range:
$0.70
$0.824
52-Week Range:
$0.6765
$2.39
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
0.8089 | 6.29M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immuron Limited Adr Stock (IMRN) Latest News
Operating cash flow per share of Immuron Limited Sponsored ADR – GETTEX:ANWA - TradingView
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Sarasota Herald-Tribune
Immuron (NASDAQ: IMRN) boosts cash, pursues partners for IMM-124E and IMM-529 - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - GlobeNewswire Inc.
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - progress-index.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron Reports Continued Sales Growth - Finviz
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Spike Watch & Smart Investment Allocation Insights - DonanımHaber
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com Australia
Orla Mining Ltd (ORLA) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com India
Immuron Limited announces quotation of new securities on ASX - MSN
Check Out IHS Holding Ltd (IHS)’s Trade Data Rather Than the Analysts’ Views - setenews.com
You might want to take a look at Embecta Corp (EMBC) now - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView — Track All Markets
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - FinancialContent
Why Immuron Limited (ANW) stock gets analyst attentionJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
IMRN Stock Price and Chart — NASDAQ:IMRN - TradingView
How Immuron Limited Depositary Receipt stock benefits from global expansion2025 Macro Impact & AI Driven Price Forecasts - Fundação Cultural do Pará
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Holdings of Immuron Limited ADR (IMRN) are aligned with the stars - Setenews
Immuron Limited Receives FDA Approval for IMM-529 Investigational New Drug Application for Clostridioides difficile Infection Treatment - Quiver Quantitative
Immuron IMM-529 IND approved by FDA - GlobeNewswire
Immuron CEO to Present at AusBiotech Invest 2025 Conference - MSN
Immuron Announces Clinical Trial Update - Sahm
Immuron Ltd (IMC:ASX) - smallcaps.com.au
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):